Pillar Biosciences takes cfDNA and cfRNA screening into 2,000-patient LC-SCRUM-Asia lung cancer project
LSI Medience has validated Pillar’s oncoReveal Essential+ for cfDNA and cfRNA screening, with approximately 2,000 lung cancer patients expected to enter testing over two years.